Review
Evolving Infection Risk and Management in Acute Leukemia in the Era of Modern Antileukemia Therapy
Rui Zhang1,#, Meng Li1,#, Hao Zhou1,*
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
#, Authors contributed equally. *, Correspondence Hao Zhou, MD, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. E-mail: zhouhao@hust.edu.cn. Received: June 29, 2026. Accepted: July 11, 2026. Published online: November 16, 2026. Cite this paper: Rui Zhang, Meng Li, Hao Zhou. Evolving infection risk and management in acute leukemia in the era of modern antileukemia therapy. Global Journal of Microbiology, 2026;7(2):8-23. http://naturescholars.com/gjmic.070202. https://doi.org/10.46633/gjmic.070202. Copyright © 2026 by Scholars Publishing, LLC.
Abstract
Background: Infectious complications remain the leading cause of morbidity and treatment-related mortality in patients with acute leukemia. Over the past two decades, the treatment of acute leukemia has shifted from conventional intensive chemotherapy toward targeted agents, antibody–drug conjugates, bispecific antibodies, and CAR T-cell therapies. These advances have substantially changed the epidemiology, spectrum, and mechanisms of infection. Methods: This review synthesizes evidence from pivotal clinical trials, real-world observational studies, and clinical practice guidelines. We evaluated infection-related adverse events reported in clinical trials of novel agents, including venetoclax, FLT3 and IDH inhibitors, bispecific T-cell engagers, CAR T-cell therapies, and menin inhibitors. We also reviewed real-world evidence on antimicrobial resistance, drug–drug interactions, and prophylactic strategies. Results: Infection risk in acute leukemia was historically dominated by prolonged neutropenia, mucosal barrier injury, and invasive fungal disease. Subsequent advances in supportive care were accompanied by increasing antimicrobial resistance and the introduction of targeted therapies, which began to alter infection patterns. More recently, novel therapies have further changed the nature of infectious risk. The focus has shifted from neutropenia alone to treatment-specific immune defects, including prolonged cytopenias, B-cell depletion, hypogammaglobulinemia, and viral reactivation. Differentiation syndrome and cytokine release syndrome may also resemble infection and complicate diagnosis. Real-world studies often report higher infection rates than pivotal trials, particularly among older patients and those with comorbidities. Conclusions: Infection risk in acute leukemia is no longer determined by neutropenia alone. It has become a therapy-specific challenge that requires mechanism-based risk stratification and individualized prophylaxis. Better adverse event reporting, careful management of drug–drug interactions, and sustained immune support may help reduce infectious complications and improve treatment outcomes.
Keywords
Acute leukemia; infectious complications; febrile neutropenia; targeted therapy; immunotherapy; antimicrobial prophylaxis; invasive fungal disease.